Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Prevention trials

Topic: Brain proteins, microglia and lab models

Researchers conducted a trial to test the effect of omega 3 polyunsaturated fatty acid supplementation and a multidomain intervention, alone or in combination, compared with placebo, on cognitive decline in elderly adults with memory complaints. The study evaluated whether these interventions could prevent or delay cognitive impairment. Ultimately, the results showed no significant effects of the interventions on cognitive decline over the duration of the trial.

Key findings

Why it matters

A randomised, placebo-controlled trial (MAPT) testing long-term omega 3 fatty acid supplements, with or without a multidomain intervention, on thinking skills in older adults with memory complaints.

How this study scored 59/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 2 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 56 of the 95 points it could be judged on, which is 59 of 100. Total 59 of 100.56 of the 95 points we could judge = 59 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 56 of the 95 points we could judge it on, which is 59 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2017 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 2 / 2 Randomised and blinded or placebo-controlled (as stated in the record)
Times cited 6 / 7 Cited 836 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 76.0 citations a year over 11 year(s) since 2017
Impact for its field and year 6 / 6 Cited 56.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 4 / 4 Cited 251 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Cécilia Marelli: h-index 42 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 48 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 28359749)
Free to read 0 / 2 Behind a paywall — scores zero
Points 56 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 56 of the 95 points we could judge it on is 59 out of 100.
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 127 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Andrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., et al. (2017). Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30040-6

Vancouver

Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. The Lancet Neurology. 2017. doi:10.1016/s1474-4422(17)30040-6. PMID: 28359749.

BibTeX

@article{andrieu2017-28359749,
  author  = {Andrieu, Sandrine and Guyonnet, Sophie and Coley, Nicola and Cantet, Christelle and Bonnefoy, Marc and Bordes, Serge and Bories, Lawrence and Cufi, Marie-Noëlle and DANTOINE, THIERRY F. and Dartigues, Jean‐François and Desclaux, Françoise and Gabelle, Audrey and Gasnier, Yannick and Pesce, Alain and Sudres, Kristel and Touchon, Jacques and Robert, Philippe Henri and Rouaud, Olivier and Legrand, Philippe and Payoux, Pierre and Caubère, Jean-Paul and Weiner, Michael W. and Carrié, Isabelle and Ousset, Pierre-Jean and Vellas, Bruno J. and Vellas, Bruno and Brigitte, Lauréane and Faisant, Catherine and Lala, Françoise and Delrieu, Julien and Villars, Hélène and Combrouze, Emeline and Badufle, Carole and Zueras, Audrey and Morin, Christophe and van Kan, Gabor Abellán and Dupuy, Charlotte and Rolland, Yves and Caillaud, Céline and Fougère, Bertrand and Willis, Sherry L. and Belleville, Sylvie and Gilbert, Brigitte and Fontaine, Francine S. and Marcet, Isabelle and Delva, Fleur and Foubert, Alexandra and Cerda, Sandrine and Noëlle-Cuffi, Marie and Costes, Corinne and Manckoundia, Patrick and Quipourt, Valérie and Marilier, Sophie and Franon, Evelyne and Pader, Marie-Laure and Basset, Marie-France and Lapoujade, Bruno and Faure, Valérie and Li, Michael and Tong, Yung and Malick-Loiseau, Christine and Cazaban-Campistron, Evelyne and Blatge, Colette and Dantoine, Thierry and Laubarie-Mouret, Cécile and Saulnier, Isabelle and Clément, Jean-Pierre and Picat, Marie-Agnès and Bernard‐Bourzeix, Laurence and Willebois, Stéphanie and Désormais, Iléana and Cardinaud, Noëlle and Livet, Pierre and Rebaudet, Pascale and Gédéon, Claire and Burdet, Catherine and Terracol, Flavien and Roth, Stéphanie and Chaillou, Sylvie and Louchart, Sandrine and Lebrun, Nicolas and Barro-Belaygues, Nadège and Bennys, Karim and Romano, Aurélia and Touati, Lynda and Marelli, Cécilia and Pays, Cécile and Le Duff, Franck and Gervais, Claire and Gonfrier, Sebastien and Begorre, Danièle and Carpuat, Christian and Khales, Khaled and Lefebvre, Jean-François and El Idrissi, Samira Misbah and Skolil, Pierre and Salles, Jean-Pierre and Dufouil, Carole and Lehéricy, Stéphane and Chupin, Marie and Mangin, Jean‐François and Bouhayia, Ali and Allard, Michèle and Ricolfi, Frédéric and Dubois, Dominique and Paule, Marie and Martel, B. and Cotton, François and Bonafé, Alain and Chanalet, S. and Hugon, Françoise and Bonneville, Fabrice and Cognard, Christophe and Chollet, François and Voisin, Thierry and Peiffer, Sophie and Hitzel, Anne and Zanca, Michel and Monteil, Jacques and Darcourt, Jacques and Molinier, Laurent and Derumeaux, Hélène and Costa, Nadège and Vincent, Christian and Perret, Bertrand and Vinel, Claire and Olivier, Pascale},
  title   = {{Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial}},
  journal = {The Lancet Neurology},
  year    = {2017},
  doi     = {10.1016/s1474-4422(17)30040-6},
  pmid    = {28359749},
  url     = {https://doi.org/10.1016/s1474-4422(17)30040-6}
}

Related studies in Prevention trials

Also tagged “cognitive-function”

1,118 studies in the library carry the topic tag “cognitive-function”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.

Similar studies

More on Prevention trials

See all studies in Prevention trials →